| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Immunologic Deficiency Syndromes | 30 | 2026 | 211 | 6.910 |
Why?
|
| Allergy and Immunology | 10 | 2017 | 30 | 3.160 |
Why?
|
| Severe Combined Immunodeficiency | 9 | 2026 | 107 | 2.150 |
Why?
|
| Genetic Therapy | 8 | 2025 | 713 | 1.370 |
Why?
|
| Tryptases | 2 | 2021 | 17 | 1.310 |
Why?
|
| Mast Cells | 2 | 2021 | 68 | 1.270 |
Why?
|
| DiGeorge Syndrome | 4 | 2011 | 83 | 1.050 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 10 | 2026 | 1280 | 0.910 |
Why?
|
| T-Lymphocytes | 14 | 2022 | 1722 | 0.870 |
Why?
|
| Hypersensitivity | 6 | 2011 | 227 | 0.840 |
Why?
|
| Phospholipase C gamma | 1 | 2024 | 27 | 0.810 |
Why?
|
| HIV Infections | 10 | 2021 | 2049 | 0.780 |
Why?
|
| Immune System Diseases | 3 | 2014 | 58 | 0.710 |
Why?
|
| Urticaria | 1 | 2021 | 20 | 0.670 |
Why?
|
| Mastocytosis, Systemic | 1 | 2020 | 8 | 0.630 |
Why?
|
| Hypereosinophilic Syndrome | 1 | 2020 | 8 | 0.630 |
Why?
|
| Immunotherapy | 5 | 2017 | 768 | 0.630 |
Why?
|
| Granulomatous Disease, Chronic | 5 | 2025 | 68 | 0.590 |
Why?
|
| Phenotype | 5 | 2024 | 4497 | 0.580 |
Why?
|
| Leukemia | 3 | 2020 | 387 | 0.580 |
Why?
|
| Immune System | 2 | 2010 | 100 | 0.550 |
Why?
|
| Humans | 74 | 2026 | 131163 | 0.540 |
Why?
|
| B-Lymphocytes | 8 | 2011 | 509 | 0.540 |
Why?
|
| Disaster Medicine | 1 | 2017 | 9 | 0.530 |
Why?
|
| Genetic Diseases, Inborn | 1 | 2021 | 468 | 0.520 |
Why?
|
| Genetic Testing | 2 | 2026 | 1106 | 0.520 |
Why?
|
| Thiazolidinediones | 1 | 2017 | 81 | 0.500 |
Why?
|
| Cytokines | 6 | 2011 | 1339 | 0.500 |
Why?
|
| Autoimmunity | 3 | 2018 | 175 | 0.490 |
Why?
|
| Cyclonic Storms | 1 | 2017 | 82 | 0.490 |
Why?
|
| rab GTP-Binding Proteins | 1 | 2016 | 52 | 0.480 |
Why?
|
| Wiskott-Aldrich Syndrome | 2 | 2025 | 25 | 0.480 |
Why?
|
| Neonatal Screening | 4 | 2026 | 207 | 0.470 |
Why?
|
| Agammaglobulinemia | 4 | 2025 | 42 | 0.460 |
Why?
|
| DNA Helicases | 1 | 2016 | 239 | 0.440 |
Why?
|
| Killer Cells, Natural | 2 | 2016 | 355 | 0.440 |
Why?
|
| Drug Hypersensitivity | 5 | 2011 | 101 | 0.390 |
Why?
|
| Autoimmune Diseases | 4 | 2011 | 262 | 0.350 |
Why?
|
| Biomedical Research | 1 | 2017 | 561 | 0.340 |
Why?
|
| Transmembrane Activator and CAML Interactor Protein | 1 | 2011 | 3 | 0.340 |
Why?
|
| Immunoglobulins, Intravenous | 5 | 2016 | 148 | 0.340 |
Why?
|
| Anaphylaxis | 2 | 2023 | 94 | 0.330 |
Why?
|
| Physicians | 1 | 2017 | 635 | 0.330 |
Why?
|
| Immunoglobulins | 2 | 2016 | 152 | 0.320 |
Why?
|
| Biomarkers | 1 | 2020 | 3385 | 0.320 |
Why?
|
| Animals | 18 | 2025 | 33912 | 0.320 |
Why?
|
| Malnutrition | 4 | 2021 | 163 | 0.320 |
Why?
|
| Smith-Magenis Syndrome | 1 | 2011 | 107 | 0.320 |
Why?
|
| Immunity | 3 | 2010 | 178 | 0.310 |
Why?
|
| Histocompatibility Antigens | 1 | 2010 | 17 | 0.310 |
Why?
|
| Transplantation Immunology | 1 | 2010 | 40 | 0.310 |
Why?
|
| Bone Marrow Transplantation | 2 | 2010 | 589 | 0.310 |
Why?
|
| Immunity, Innate | 3 | 2011 | 406 | 0.300 |
Why?
|
| Receptors, Interleukin-2 | 2 | 2007 | 37 | 0.300 |
Why?
|
| Infant | 17 | 2023 | 13352 | 0.290 |
Why?
|
| Lymphopenia | 3 | 2023 | 33 | 0.290 |
Why?
|
| Interleukin-7 | 1 | 2009 | 46 | 0.290 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2009 | 117 | 0.280 |
Why?
|
| Antigens, Fungal | 1 | 2008 | 32 | 0.280 |
Why?
|
| CD3 Complex | 3 | 2008 | 96 | 0.280 |
Why?
|
| Tetanus Toxoid | 1 | 2008 | 48 | 0.280 |
Why?
|
| Candida | 1 | 2008 | 79 | 0.270 |
Why?
|
| Down Syndrome | 1 | 2011 | 233 | 0.270 |
Why?
|
| Respiratory Tract Infections | 1 | 2011 | 298 | 0.270 |
Why?
|
| Child, Preschool | 15 | 2023 | 15110 | 0.260 |
Why?
|
| Receptors, Cell Surface | 2 | 2007 | 420 | 0.260 |
Why?
|
| Infant, Newborn | 8 | 2026 | 8635 | 0.260 |
Why?
|
| Organ Transplantation | 1 | 2010 | 175 | 0.260 |
Why?
|
| X-Linked Combined Immunodeficiency Diseases | 1 | 2007 | 2 | 0.260 |
Why?
|
| Graft Rejection | 3 | 2010 | 552 | 0.260 |
Why?
|
| rab27 GTP-Binding Proteins | 2 | 2016 | 5 | 0.250 |
Why?
|
| Antigens, Bacterial | 1 | 2008 | 319 | 0.240 |
Why?
|
| Mastocytosis | 2 | 2021 | 7 | 0.240 |
Why?
|
| Th1 Cells | 2 | 2005 | 158 | 0.230 |
Why?
|
| Lymphoma, B-Cell | 1 | 2007 | 147 | 0.230 |
Why?
|
| Lymphocyte Count | 4 | 2009 | 118 | 0.230 |
Why?
|
| Membrane Proteins | 4 | 2025 | 1590 | 0.230 |
Why?
|
| Vaccines, DNA | 1 | 2005 | 44 | 0.220 |
Why?
|
| Environment | 2 | 2021 | 149 | 0.220 |
Why?
|
| Exodeoxyribonucleases | 1 | 2025 | 52 | 0.220 |
Why?
|
| Autoimmune Diseases of the Nervous System | 1 | 2025 | 37 | 0.220 |
Why?
|
| Child | 17 | 2023 | 26341 | 0.210 |
Why?
|
| Arthropod Venoms | 1 | 2023 | 8 | 0.200 |
Why?
|
| Ants | 1 | 2023 | 7 | 0.200 |
Why?
|
| High-Throughput Nucleotide Sequencing | 3 | 2017 | 889 | 0.200 |
Why?
|
| Nervous System Malformations | 1 | 2025 | 135 | 0.200 |
Why?
|
| Adolescent | 9 | 2021 | 20987 | 0.190 |
Why?
|
| Insect Bites and Stings | 1 | 2023 | 41 | 0.190 |
Why?
|
| Cord Blood Stem Cell Transplantation | 1 | 2023 | 57 | 0.190 |
Why?
|
| Phosphoproteins | 1 | 2025 | 448 | 0.190 |
Why?
|
| Adaptor Proteins, Signal Transducing | 2 | 2017 | 619 | 0.190 |
Why?
|
| Immunosuppressive Agents | 2 | 2021 | 663 | 0.190 |
Why?
|
| Precision Medicine | 1 | 2026 | 388 | 0.180 |
Why?
|
| Male | 19 | 2024 | 64957 | 0.180 |
Why?
|
| Wounds and Injuries | 2 | 2021 | 398 | 0.180 |
Why?
|
| Signal Transduction | 4 | 2009 | 4686 | 0.180 |
Why?
|
| Skin Diseases | 2 | 2022 | 143 | 0.180 |
Why?
|
| Gene Editing | 1 | 2025 | 238 | 0.180 |
Why?
|
| Clinical Trials as Topic | 4 | 2017 | 1129 | 0.180 |
Why?
|
| Cell Proliferation | 2 | 2010 | 2465 | 0.180 |
Why?
|
| Mutation | 7 | 2024 | 6099 | 0.180 |
Why?
|
| Candidiasis, Chronic Mucocutaneous | 1 | 2021 | 5 | 0.180 |
Why?
|
| Recombinant Fusion Proteins | 3 | 2009 | 688 | 0.180 |
Why?
|
| Genetic Vectors | 2 | 2025 | 892 | 0.180 |
Why?
|
| Cetirizine | 1 | 2021 | 4 | 0.170 |
Why?
|
| Anemia, Sideroblastic | 1 | 2021 | 15 | 0.170 |
Why?
|
| HIV-1 | 3 | 2001 | 490 | 0.170 |
Why?
|
| Anti-Allergic Agents | 1 | 2021 | 28 | 0.170 |
Why?
|
| Twins, Monozygotic | 1 | 2021 | 124 | 0.160 |
Why?
|
| Gene Products, tat | 3 | 1997 | 27 | 0.160 |
Why?
|
| HIV | 2 | 2002 | 174 | 0.160 |
Why?
|
| Antibody Formation | 4 | 2010 | 227 | 0.160 |
Why?
|
| Metabolism, Inborn Errors | 1 | 2021 | 125 | 0.160 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2021 | 218 | 0.160 |
Why?
|
| Opportunistic Infections | 2 | 2015 | 69 | 0.160 |
Why?
|
| Phenobarbital | 1 | 2000 | 32 | 0.150 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2007 | 500 | 0.150 |
Why?
|
| Metabolic Diseases | 1 | 2021 | 143 | 0.150 |
Why?
|
| Transcription Factors | 2 | 2007 | 2406 | 0.150 |
Why?
|
| Antibodies, Monoclonal | 3 | 2011 | 981 | 0.150 |
Why?
|
| Immunologic Factors | 2 | 2011 | 190 | 0.150 |
Why?
|
| Female | 17 | 2024 | 70963 | 0.140 |
Why?
|
| NF-kappa B p50 Subunit | 1 | 2018 | 10 | 0.140 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2022 | 502 | 0.140 |
Why?
|
| Thymectomy | 1 | 2018 | 24 | 0.140 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 2018 | 71 | 0.140 |
Why?
|
| Quality of Life | 3 | 2026 | 2082 | 0.140 |
Why?
|
| Dendritic Cells | 3 | 2008 | 439 | 0.140 |
Why?
|
| Gene Products, rev | 2 | 1997 | 11 | 0.140 |
Why?
|
| Splenectomy | 1 | 2018 | 61 | 0.140 |
Why?
|
| Angioedema | 2 | 2009 | 21 | 0.130 |
Why?
|
| Puerto Rico | 1 | 2017 | 54 | 0.130 |
Why?
|
| Antiretroviral Therapy, Highly Active | 2 | 2009 | 256 | 0.130 |
Why?
|
| Immunity, Humoral | 3 | 2016 | 74 | 0.130 |
Why?
|
| Diagnosis, Differential | 2 | 2020 | 1882 | 0.130 |
Why?
|
| Immunization, Passive | 2 | 2009 | 120 | 0.130 |
Why?
|
| Practice Guidelines as Topic | 3 | 2020 | 1295 | 0.130 |
Why?
|
| Anticonvulsants | 1 | 2000 | 363 | 0.130 |
Why?
|
| Genetic Variation | 1 | 2024 | 1559 | 0.130 |
Why?
|
| T-Lymphocyte Subsets | 2 | 2009 | 193 | 0.130 |
Why?
|
| AIDS Vaccines | 2 | 2009 | 35 | 0.120 |
Why?
|
| Genomics | 2 | 2022 | 1621 | 0.120 |
Why?
|
| Toll-Like Receptors | 2 | 2007 | 83 | 0.120 |
Why?
|
| Microfilament Proteins | 1 | 2017 | 269 | 0.110 |
Why?
|
| Cohort Studies | 3 | 2011 | 5063 | 0.110 |
Why?
|
| Immunoglobulin G | 3 | 2009 | 786 | 0.110 |
Why?
|
| Prenatal Diagnosis | 1 | 2019 | 612 | 0.110 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2017 | 484 | 0.110 |
Why?
|
| Disease Management | 2 | 2015 | 558 | 0.110 |
Why?
|
| Prognosis | 2 | 2020 | 4886 | 0.100 |
Why?
|
| History, 21st Century | 1 | 2015 | 263 | 0.100 |
Why?
|
| Common Variable Immunodeficiency | 2 | 2011 | 30 | 0.100 |
Why?
|
| CD4 Antigens | 2 | 2003 | 54 | 0.100 |
Why?
|
| Repressor Proteins | 1 | 2017 | 760 | 0.090 |
Why?
|
| Pneumococcal Vaccines | 2 | 2012 | 174 | 0.090 |
Why?
|
| Leukocyte-Adhesion Deficiency Syndrome | 1 | 2012 | 3 | 0.090 |
Why?
|
| Hypersensitivity, Immediate | 1 | 2012 | 32 | 0.090 |
Why?
|
| Unrelated Donors | 1 | 2011 | 72 | 0.090 |
Why?
|
| Mutation, Missense | 1 | 2016 | 919 | 0.090 |
Why?
|
| Cytidine Deaminase | 1 | 2011 | 31 | 0.090 |
Why?
|
| Toll-Like Receptor 9 | 1 | 2011 | 23 | 0.080 |
Why?
|
| Angioedemas, Hereditary | 1 | 2011 | 6 | 0.080 |
Why?
|
| Models, Immunological | 1 | 2011 | 36 | 0.080 |
Why?
|
| Injections, Subcutaneous | 2 | 2016 | 136 | 0.080 |
Why?
|
| Lymphocyte Subsets | 1 | 2011 | 40 | 0.080 |
Why?
|
| Immunoglobulin Isotypes | 1 | 2010 | 14 | 0.080 |
Why?
|
| Antibody-Producing Cells | 1 | 2010 | 5 | 0.080 |
Why?
|
| Immunity, Cellular | 2 | 2008 | 197 | 0.080 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2021 | 3436 | 0.080 |
Why?
|
| Genes, X-Linked | 1 | 2010 | 59 | 0.080 |
Why?
|
| Immune Reconstitution Inflammatory Syndrome | 1 | 2009 | 18 | 0.080 |
Why?
|
| Haploinsufficiency | 1 | 2011 | 266 | 0.070 |
Why?
|
| Immune Tolerance | 1 | 2010 | 151 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 2011 | 363 | 0.070 |
Why?
|
| Young Adult | 3 | 2016 | 10103 | 0.070 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 1 | 2008 | 33 | 0.070 |
Why?
|
| RNA, Messenger | 2 | 2012 | 2550 | 0.070 |
Why?
|
| Complement System Proteins | 2 | 2005 | 58 | 0.070 |
Why?
|
| Lymphocyte Depletion | 1 | 2008 | 124 | 0.070 |
Why?
|
| Forkhead Transcription Factors | 1 | 2011 | 371 | 0.070 |
Why?
|
| Base Sequence | 2 | 2011 | 2730 | 0.070 |
Why?
|
| Antigen Presentation | 1 | 2008 | 110 | 0.070 |
Why?
|
| Neoplasm Proteins | 1 | 2012 | 680 | 0.070 |
Why?
|
| Uremia | 1 | 2008 | 33 | 0.070 |
Why?
|
| Chromosome Deletion | 1 | 2011 | 653 | 0.070 |
Why?
|
| Tissue Donors | 1 | 2011 | 506 | 0.070 |
Why?
|
| Transplantation Conditioning | 1 | 2009 | 328 | 0.070 |
Why?
|
| Complement C1 Inhibitor Protein | 1 | 2007 | 7 | 0.070 |
Why?
|
| Antigens, CD1d | 1 | 2007 | 20 | 0.070 |
Why?
|
| Antigens, CD1 | 1 | 2007 | 23 | 0.060 |
Why?
|
| Immunoglobulin E | 1 | 2008 | 215 | 0.060 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 2023 | 219 | 0.060 |
Why?
|
| Homeodomain Proteins | 1 | 2010 | 555 | 0.060 |
Why?
|
| Adult | 5 | 2016 | 31282 | 0.060 |
Why?
|
| NADPH Oxidases | 2 | 2022 | 109 | 0.060 |
Why?
|
| Membrane Glycoproteins | 2 | 2010 | 405 | 0.060 |
Why?
|
| Vaccination | 1 | 2012 | 1060 | 0.060 |
Why?
|
| Antigens, CD | 1 | 2008 | 410 | 0.060 |
Why?
|
| Retroviridae | 1 | 2007 | 182 | 0.060 |
Why?
|
| Polymerase Chain Reaction | 1 | 2010 | 1447 | 0.060 |
Why?
|
| Transplantation, Autologous | 1 | 2007 | 254 | 0.060 |
Why?
|
| Neck | 1 | 2007 | 140 | 0.060 |
Why?
|
| Gamma Rays | 1 | 2006 | 38 | 0.060 |
Why?
|
| Diabetes Complications | 1 | 2008 | 197 | 0.060 |
Why?
|
| Antibodies, Bacterial | 1 | 2008 | 406 | 0.060 |
Why?
|
| Neoplasms | 1 | 2021 | 3016 | 0.060 |
Why?
|
| Transduction, Genetic | 1 | 2007 | 276 | 0.060 |
Why?
|
| Respiratory System | 1 | 2006 | 94 | 0.060 |
Why?
|
| Infection Control | 1 | 2007 | 158 | 0.060 |
Why?
|
| Cell Line | 3 | 2012 | 2552 | 0.060 |
Why?
|
| Surgical Procedures, Operative | 1 | 2008 | 225 | 0.060 |
Why?
|
| Cloning, Molecular | 2 | 1997 | 780 | 0.050 |
Why?
|
| Antarctic Regions | 1 | 2004 | 8 | 0.050 |
Why?
|
| Adenosine Deaminase | 1 | 2004 | 89 | 0.050 |
Why?
|
| Self Administration | 1 | 2004 | 49 | 0.050 |
Why?
|
| Th2 Cells | 1 | 2005 | 188 | 0.050 |
Why?
|
| Substrate Specificity | 1 | 2025 | 287 | 0.050 |
Why?
|
| Allergens | 1 | 2007 | 344 | 0.050 |
Why?
|
| Prevalence | 1 | 2011 | 2701 | 0.050 |
Why?
|
| Inflammation | 1 | 2011 | 1489 | 0.050 |
Why?
|
| Chromosomes, Human, X | 1 | 2004 | 155 | 0.050 |
Why?
|
| Proteolysis | 1 | 2025 | 200 | 0.050 |
Why?
|
| Trichosporon | 1 | 2003 | 4 | 0.050 |
Why?
|
| ZAP-70 Protein-Tyrosine Kinase | 1 | 2023 | 13 | 0.050 |
Why?
|
| src Homology Domains | 1 | 2023 | 34 | 0.050 |
Why?
|
| Phytohemagglutinins | 1 | 2003 | 12 | 0.050 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2009 | 789 | 0.050 |
Why?
|
| Nucleoside Deaminases | 1 | 2003 | 23 | 0.050 |
Why?
|
| Cytosine Deaminase | 1 | 2003 | 15 | 0.050 |
Why?
|
| Busulfan | 1 | 2023 | 51 | 0.050 |
Why?
|
| CD8 Antigens | 1 | 2003 | 39 | 0.050 |
Why?
|
| Liver Transplantation | 1 | 2012 | 1147 | 0.050 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2003 | 71 | 0.050 |
Why?
|
| Injections, Intravenous | 1 | 2003 | 239 | 0.050 |
Why?
|
| Respiratory Burst | 1 | 2022 | 8 | 0.050 |
Why?
|
| Follow-Up Studies | 2 | 2012 | 5196 | 0.050 |
Why?
|
| HEK293 Cells | 1 | 2025 | 801 | 0.050 |
Why?
|
| tat Gene Products, Human Immunodeficiency Virus | 3 | 1997 | 31 | 0.050 |
Why?
|
| Evidence-Based Medicine | 2 | 2016 | 645 | 0.050 |
Why?
|
| Vaccines | 1 | 2007 | 388 | 0.050 |
Why?
|
| Amino Acid Substitution | 2 | 2016 | 405 | 0.050 |
Why?
|
| Mycoses | 1 | 2003 | 110 | 0.040 |
Why?
|
| RNA Splice Sites | 1 | 2022 | 92 | 0.040 |
Why?
|
| Cell Communication | 1 | 2003 | 188 | 0.040 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2025 | 229 | 0.040 |
Why?
|
| T-Box Domain Proteins | 1 | 2003 | 123 | 0.040 |
Why?
|
| Retrospective Studies | 4 | 2012 | 17753 | 0.040 |
Why?
|
| United States | 1 | 2017 | 12072 | 0.040 |
Why?
|
| CARD Signaling Adaptor Proteins | 1 | 2021 | 42 | 0.040 |
Why?
|
| Reference Values | 1 | 2003 | 676 | 0.040 |
Why?
|
| Cell Division | 1 | 2003 | 718 | 0.040 |
Why?
|
| Nucleotidyltransferases | 1 | 2021 | 47 | 0.040 |
Why?
|
| Virus Replication | 2 | 2002 | 608 | 0.040 |
Why?
|
| Prospective Studies | 2 | 2023 | 6459 | 0.040 |
Why?
|
| Cyclophosphamide | 1 | 2023 | 428 | 0.040 |
Why?
|
| Arginine | 1 | 2023 | 340 | 0.040 |
Why?
|
| Graft vs Host Disease | 3 | 2011 | 694 | 0.040 |
Why?
|
| Cytopathogenic Effect, Viral | 2 | 1997 | 28 | 0.040 |
Why?
|
| rev Gene Products, Human Immunodeficiency Virus | 2 | 1997 | 15 | 0.040 |
Why?
|
| Gene Dosage | 1 | 2021 | 435 | 0.040 |
Why?
|
| Lymphocyte Activation | 2 | 2000 | 633 | 0.040 |
Why?
|
| Homozygote | 1 | 2021 | 533 | 0.040 |
Why?
|
| Postoperative Complications | 1 | 2012 | 3147 | 0.040 |
Why?
|
| Treatment Outcome | 4 | 2011 | 12936 | 0.040 |
Why?
|
| Space Flight | 1 | 2003 | 177 | 0.040 |
Why?
|
| Reactive Oxygen Species | 1 | 2022 | 521 | 0.040 |
Why?
|
| Mucocutaneous Lymph Node Syndrome | 1 | 2000 | 78 | 0.040 |
Why?
|
| Primary Health Care | 1 | 2005 | 775 | 0.040 |
Why?
|
| Fever | 1 | 2021 | 312 | 0.040 |
Why?
|
| Longitudinal Studies | 1 | 2003 | 1490 | 0.040 |
Why?
|
| Genes, tat | 2 | 1995 | 10 | 0.030 |
Why?
|
| Genome, Human | 1 | 2005 | 1321 | 0.030 |
Why?
|
| Alleles | 1 | 2021 | 1673 | 0.030 |
Why?
|
| Immunomodulation | 1 | 2016 | 84 | 0.030 |
Why?
|
| Piebaldism | 1 | 2016 | 3 | 0.030 |
Why?
|
| Albinism | 1 | 2016 | 8 | 0.030 |
Why?
|
| Consanguinity | 1 | 2016 | 115 | 0.030 |
Why?
|
| Leukocytes, Mononuclear | 1 | 1997 | 354 | 0.030 |
Why?
|
| HeLa Cells | 1 | 1997 | 686 | 0.030 |
Why?
|
| Genes, rev | 1 | 1995 | 5 | 0.030 |
Why?
|
| Cell Differentiation | 1 | 2003 | 1928 | 0.030 |
Why?
|
| Genes, Recessive | 1 | 2016 | 193 | 0.030 |
Why?
|
| Amino Acid Sequence | 3 | 2012 | 2395 | 0.030 |
Why?
|
| Advisory Committees | 1 | 2015 | 150 | 0.030 |
Why?
|
| Cells, Cultured | 2 | 1997 | 2885 | 0.030 |
Why?
|
| Molecular Sequence Data | 3 | 2012 | 3464 | 0.030 |
Why?
|
| Lymphohistiocytosis, Hemophagocytic | 1 | 2016 | 160 | 0.030 |
Why?
|
| Bacteriophage phi X 174 | 1 | 2012 | 4 | 0.020 |
Why?
|
| Rabies Vaccines | 1 | 2012 | 11 | 0.020 |
Why?
|
| Salmonella Vaccines | 1 | 2012 | 7 | 0.020 |
Why?
|
| Gene Expression | 1 | 1997 | 1481 | 0.020 |
Why?
|
| Haemophilus Vaccines | 1 | 2012 | 33 | 0.020 |
Why?
|
| Bacterial Capsules | 1 | 2012 | 42 | 0.020 |
Why?
|
| Pedigree | 1 | 2016 | 1677 | 0.020 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 2012 | 115 | 0.020 |
Why?
|
| Protein Binding | 1 | 2016 | 1652 | 0.020 |
Why?
|
| Sibling Relations | 1 | 2011 | 12 | 0.020 |
Why?
|
| Immunoprecipitation | 1 | 2012 | 189 | 0.020 |
Why?
|
| Antibodies | 1 | 2012 | 322 | 0.020 |
Why?
|
| DNA Copy Number Variations | 1 | 2016 | 1029 | 0.020 |
Why?
|
| Codon | 1 | 2010 | 93 | 0.020 |
Why?
|
| B-Cell Activating Factor | 1 | 2010 | 4 | 0.020 |
Why?
|
| Educational Status | 1 | 2011 | 279 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2012 | 1013 | 0.020 |
Why?
|
| NADPH Oxidase 2 | 1 | 2010 | 38 | 0.020 |
Why?
|
| Cell Migration Inhibition | 1 | 2009 | 8 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2012 | 765 | 0.020 |
Why?
|
| Genetic Diseases, X-Linked | 1 | 2010 | 81 | 0.020 |
Why?
|
| Mice | 2 | 2021 | 18301 | 0.020 |
Why?
|
| Transplantation, Homologous | 1 | 2011 | 670 | 0.020 |
Why?
|
| Delayed Diagnosis | 1 | 2011 | 131 | 0.020 |
Why?
|
| Immunophenotyping | 1 | 2010 | 332 | 0.020 |
Why?
|
| Mice, Mutant Strains | 1 | 2010 | 356 | 0.020 |
Why?
|
| Activities of Daily Living | 1 | 2011 | 386 | 0.020 |
Why?
|
| Complementary Therapies | 1 | 2009 | 45 | 0.020 |
Why?
|
| Spleen | 1 | 2010 | 258 | 0.020 |
Why?
|
| Academies and Institutes | 1 | 2009 | 81 | 0.020 |
Why?
|
| Immunization | 1 | 2010 | 269 | 0.020 |
Why?
|
| Immunoglobulin A | 1 | 2009 | 201 | 0.020 |
Why?
|
| Pregnancy | 1 | 2001 | 7512 | 0.020 |
Why?
|
| Inflammation Mediators | 1 | 2009 | 226 | 0.020 |
Why?
|
| Drug Discovery | 1 | 2009 | 179 | 0.020 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2008 | 214 | 0.020 |
Why?
|
| Autoantibodies | 1 | 2010 | 451 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2009 | 1071 | 0.020 |
Why?
|
| Risk Factors | 1 | 2001 | 11074 | 0.020 |
Why?
|
| Graft Survival | 1 | 2008 | 465 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2008 | 905 | 0.020 |
Why?
|
| Phagocyte Bactericidal Dysfunction | 1 | 2005 | 1 | 0.010 |
Why?
|
| Age Factors | 1 | 2012 | 2825 | 0.010 |
Why?
|
| Luciferases | 2 | 1995 | 127 | 0.010 |
Why?
|
| Sequence Analysis, DNA | 1 | 2010 | 1692 | 0.010 |
Why?
|
| Risk | 1 | 2006 | 726 | 0.010 |
Why?
|
| Cytomegalovirus Infections | 1 | 2006 | 223 | 0.010 |
Why?
|
| Communicable Diseases | 1 | 2006 | 155 | 0.010 |
Why?
|
| Survival Rate | 1 | 2008 | 2114 | 0.010 |
Why?
|
| Nervous System Diseases | 1 | 2006 | 395 | 0.010 |
Why?
|
| Respiratory Syncytial Virus Infections | 1 | 2006 | 400 | 0.010 |
Why?
|
| Surveys and Questionnaires | 1 | 2012 | 4066 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2010 | 4738 | 0.010 |
Why?
|
| Kidney Transplantation | 1 | 2006 | 558 | 0.010 |
Why?
|
| Time Factors | 1 | 2008 | 6196 | 0.010 |
Why?
|
| Algorithms | 1 | 2005 | 1680 | 0.010 |
Why?
|
| Mental Disorders | 1 | 2006 | 910 | 0.010 |
Why?
|
| Aged | 1 | 2016 | 21025 | 0.010 |
Why?
|
| Asthma | 1 | 2006 | 922 | 0.010 |
Why?
|
| Middle Aged | 1 | 2016 | 28601 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2003 | 2065 | 0.010 |
Why?
|
| Genes, Dominant | 1 | 1995 | 242 | 0.010 |
Why?
|
| Zidovudine | 1 | 1994 | 21 | 0.010 |
Why?
|
| Transfection | 1 | 1995 | 962 | 0.010 |
Why?
|
| DNA Primers | 1 | 1994 | 599 | 0.010 |
Why?
|
| Sequence Deletion | 1 | 1995 | 516 | 0.010 |
Why?
|